The goals of our Crohn's and Colitis Clinics are to improve patient access and continuity of care; facilitate team conferencing among physicians and other providers; and provide efficient patient referral to clinic research studies and emerging therapies.
In 2002, MNGI Digestive Health opened its first clinic exclusively designed for patients with inflammatory bowel disease (IBD), a disorder which includes Crohn's Disease and Ulcerative Colitis. As the need for these highly specialized services has grown, we have since expanded the Crohn's and Colitis Clinic to all our locations.
The goals of our Crohn's and Colitis Clinics are to improve patient access and continuity of care; facilitate team conferencing among physicians and other providers; and provide efficient patient referral to clinical research studies and emerging therapies.
Electronic medical records capabilities help us communicate medication and treatment updates promptly with referring physicians.
Immunomodulator and Biologic Therapy
Traditional IBD treatments include steroids and surgery, both of which may be effective short-term, but are generally unsuccessful in maintaining remission. Significant side effects can also occur with these treatments.
Our Crohn's and Colitis Clinics specialize in the delivery of effective, leading-edge medications, including immunomodulator and biologic therapies.
Immunomodulators, such as mercaptopurine and azathioprine, and biologic treatments like Infliximab (Remicade®), Adalimumab (Humira®), Golimumab (Simponi®), Certalizumab (Cimzia®), Ustekinumab (Stelara®), Vedolizumab (Entyvio®) and Infliximab-dyyb (Inflectra®), can effectively induce and maintain remission of IBD, while limiting the need for steroids.
Highly trained nurses at our infusion therapy locations administer biological anti-inflammatory treatments, such as Remicade®, Cimzia®, Entyvio®, and Inflectra®, in a relaxed, comfortable setting.
For more information: